Dec. 20, 2013
/PRNewswire/ -- GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW" or the "Company"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today that it has filed a registration statement with the U.S. Securities and Exchange Commission ("SEC") for a proposed public offering of American Depositary Shares ("ADSs") on the NASDAQ Global Market. The number of shares to be offered and the price range for the offering have not yet been determined.
Morgan Stanley & Co. LLC and Cowen and Company, LLC are acting as joint book-running managers for the offering.
& Co. is acting as lead manager and Canaccord Genuity Inc. is acting as co-lead manager.
When available, a copy of the preliminary prospectus may be obtained from Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor,
, New York 10014; from Cowen and Company, LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue,
, 11717, Attn: Prospectus Department; from
& Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03,
55402; from Canaccord Genuity Inc., Attention: Syndicate Department, 99 High Street, 12th Floor,
A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.